Press release: Uppsala,
The subscription period for the Rights Issue will be from
Please note, however, that nominees may have a deadline for subscribing to the Rights Issue that occurs before
Summary of the Rights Issue
Subscription period:
Trading with unit rights:
Preference: For each one (1), on the record date
Unit: One (1) unit contains three (3) newly issued shares and three (3) warrants of series 2021/2022.
Subscription price: The subscription price is
Issue payment: Upon full subscription of the Rights Issue, the Company will receive approximately
Subscription undertakings and guarantees: The Rights Issue is partially secured through subscription undertakings of approximately 6,2 percent and through underwriting commitments of approximately 73,8 percent. In total, 80 percent of the Rights Issue is secured by subscription undertakings and underwriting commitments.
Subscription with preemption rights
The shareholders or representatives for such shareholders who are registered in the share register kept by
In the event that a different number of unit rights than those stated in the pre-printed issue report are exercised for subscription, the special application form available on the
Shareholders whose holdings of shares in the Company were nominee-registered with a bank or other nominee on the record date will not receive an issue report nor a special application form from
Subscription without preemption rights
Notification of subscription without preemption rights through a nominee shall be made in accordance with the instructions from the respective nominee. For subscription through an endowment insurance or an investment savings account, please contact your nominee. Notification of subscription without preemption rights is otherwise made by submitting a registration form by post or e-mail to
More information regarding the Rights Issue is available at the Company's website, www.dicot.se,
Advisors
For further information, please contact:
Göran Beijer CEO
Tel: +46 706 63 60 09
Email: goran.beijer@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
Important information
This press release is not an offer to subscribe for shares or units in Dicot and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Dicot will only be made through the EU growth prospectus that Dicot has published on its website on
This press release shall not, directly or indirectly, be released, published or distributed in or to
There is no intention to register any portion of the offer in
The Company has not authorized any offer to the public with regards to the shares or rights that are referred to in this communication in any member state of the European Economic Area (''EEA'') besides
This press release may contain certain forward-looking information that reflects Dicot's current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. Dicot makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.
https://news.cision.com/dicot-ab--publ-/r/the-subscription-period-for-dicot-s-rights-issue-begins-today-on-october-12--2021,c3430826
https://mb.cision.com/Main/17172/3430826/1479682.pdf
(c) 2021 Cision. All rights reserved., source